Immune-checkpoint inhibitor-associated diabetes compared to other diabetes types - A prospective, matched control study.
Sascha René TittelKatharina LaubnerSebastian M MeyhöferStefan KressSigrun MergerWolfram KargesFrank J WoschMarcus AltmeierMarianne PavelReinhard W Hollnull nullPublished in: Journal of diabetes (2021)
The data from this controlled study show that CPI-DM is characterized by a high prevalence of DKA, autoimmune comorbidity, and metabolic decompensation at onset. Structured diagnostic monitoring is warranted to prevent DKA and other acute endocrine complications in CPI-treated patients.
Keyphrases
- type diabetes
- cardiovascular disease
- glycemic control
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- liver failure
- multiple sclerosis
- prognostic factors
- drug induced
- metabolic syndrome
- electronic health record
- patient reported
- insulin resistance
- hepatitis b virus
- patient reported outcomes
- mechanical ventilation